Androgen receptor in salivary gland carcinoma: a review of an old marker as a possible new target

Descrição

Tipo

Artigo de periódico

Título alternativo

Primeiro orientador

Membros da banca

Resumo

The role of the androgen receptor (AR) as an immunomarker for diagnosis of salivary gland duct carcinoma (SDC) is well known. Other non-squamous cell head and neck cancers (NSCC-HN), including a small subset of salivary gland cancers (SGCs), can also express AR. With the increase in effective and powerful new generation of anti-androgen agents and drugs administered orally, more targetable AR-driven NSCC-HN, such as subsets of SGCs, should be investigated for possible expression of AR. In this review, we focus on SGC subtypes, which could express AR and describe the main androgen deprivation therapy (ADT) strategies.

Abstract

Assunto

Abiraterone acetate, Receptors, androgen, Immunohistochemistry, Carcinoma, mucoepidermoid, Carcinoma, adenoid cystic, Adenocarcinoma, Prognosis, Radiotherapy, Excision repair, Androgen antagonists, Drug therapy

Palavras-chave

Abiraterone, androgen receptor, Enzalutamide, Head and neck, immunohistochemistry, Non-squamous cell carcinoma, Salivary gland carcinoma

Citação

Curso

Endereço externo

https://onlinelibrary.wiley.com/doi/10.1111/jop.12741

Avaliação

Revisão

Suplementado Por

Referenciado Por